Skip to main content
Premium Trial:

Request an Annual Quote

Marina Stock Moved to Over-the-Counter Markets

Premium

Marina Biotech this week announced that its stock has begun trading on the over-the-counter markets after the company was unable to meet the Nasdaq's listing requirements.

"I and our board of directors have decided, at this point, that the company is not in a position to meet the listing standards of the Nasdaq stock market,” Marina President and CEO Michael French said in a statement. “By utilizing the strengths of the OTC markets, we believe we can be in a position in the future to return to a national securities exchange if we so choose."

Marina failed to meet the Nasdaq's minimum $1 bid price. As of Thursday morning, the company's shares were trading at around $0.49 each.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.